PHILADELPHIA, PA, and SOUTH SAN FRANCISCO, CA – HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, and Claritas Rx, the patient journey experts, announced today a strategic partnership to deliver a new data-driven offering that enhances commercial visibility and real-world evidence generation across the pharmaceutical product lifecycle.

The collaboration unites expansive de-identified RWD—including medical and pharmacy claims, EMR, and lab data—from HealthVerity with deeply specialized data on specialty pharmacy (SP), hub, and co-pay programs from Claritas Rx. Together, the companies aim to provide pharmaceutical manufacturers with an integrated, privacy-protected dataset that offers unmatched insight into treatment access, speed-to-therapy, and patient adherence.

For commercial teams, this means a clearer view of brand performance, optimized targeting, and better-informed access strategy decisions. For RWE and HEOR leaders, the offering supports faster, more precise evidence generation by filling critical gaps in the patient journey and enabling longitudinal analysis from prescription to outcome.

“Pharmaceutical companies are under increasing pressure to demonstrate access, effectiveness, and value with real-world data. This partnership gives our clients the depth and flexibility they need to do exactly that,” said Andrew Goldberg, COO and co-founder of HealthVerity. “By integrating our Verified data ecosystem with specialty data expertise from Claritas Rx, we can deliver greater coverage, precision, and stability—key pillars for real-time decision-making.”

“We’re thrilled to work with HealthVerity to meet the growing demand for integrated, actionable patient data,” said Michael Fitzgibbons, CEO of Claritas Rx. “Combining our specialty data insights with HealthVerity’s scalable infrastructure gives commercial, RWE and HEOR teams a powerful 360-degree view into unique patient behavior and treatment dynamics.”

The partnership enables a faster path for pharma customers using the Claritas Rx specialty aggregation platform and analytics to link its aggregated specialty pharmacy/hub/co-pay data with HealthVerity research-grade RWD. Beneficiaries include brand and commercial strategy teams, HEOR teams, and RWE researchers across top life sciences companies. 

Learn more about the partnership or explore the data offering here.

About HealthVerity

HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry’s largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, regulatory decision-making, and public health.

Media Contact:

HealthVerity
info@healthverity.com

About Claritas Rx

Based in South San Francisco, CA, Claritas Rx helps rare disease and specialty brands remove the barriers that keep patients from accessing and staying on the treatments they need. By uniting the most complete view of the patient journey with purpose-built technologies, we predict and resolve access challenges before they disrupt care. Our intelligent solutions combine advanced analytics, real-world data, AI, and in-line CRM capabilities to increase start and refill rates, reduce abandonment, and improve brand performance. For more information, visit www.ClaritasRx.com.

Media Contact:

Claritas Rx
ebrennan@claritasrx.com

PHILADELPHIA, PA – HealthVerity, the leader in real-world data (RWD) technologies and privacy-compliant data exchange, today announced the launch of taXonomy Pathways, a groundbreaking framework that unites closed payer claims, lab results and electronic health records (EHR), including physician notes into research-ready therapeutic area-specific datasets designed to close critical evidence gaps across life sciences, payers, government and consulting partners.

Therapeutic areas from taXonomy Pathways are anchored by the nation’s largest source of closed payer claims, spanning hundreds of payers, nine years of adjudicated history and more than 300 million patients across all pay types. The acclaimed taXonomy data model synthesizes multi-payer medical and pharmacy claims and eligibility into a streamlined relational dataset that enables efficient ingestion and onboarding. Teams are able to get up to speed quickly and translate study protocols to valuable analysis . Further innovation comes from expanding beyond claims into novel patient features that are only available from lab results and EHR, including physician notes, that fundamentally enrich the patient journey.

In diabetes and obesity cohorts, repeated measures such as BMI, HbA1c, weight, blood pressure and lipid panels provide a comprehensive view of disease progression and treatment response. For heart failure, echocardiogram‑derived left‑ventricular ejection fraction and cardiovascular labs illuminate cardiac function, guideline‑directed therapy uptake and hospitalisation risk. In oncology, lab results confirm diagnosis and provide prognostic insight essential for precision medicine, while for neurology and rare diseases, structured EMR and clinical notes reveal symptom‑level detail, adverse events and real‑world outcomes that claims cannot capture.

“With taXonomy Pathways, we are simplifying the assembly of longitudinal patient journeys” said Andrew Kress, CEO of HealthVerity. “Now, researchers can seamlessly access claims, EHR, labs and clinical notes in a single, research-ready framework that accelerates time to evidence without compromising rigor, privacy or scale. This is a game-changer for real-world evidence, safety and beyond.”

taXonomy Pathways includes lab results from two leading outpatient labs, representing more than 60% of U.S. testing, including genetic assays. Lab values and collection dates align with exposure windows from medical and pharmacy claims to derive baselines and quantify treatment response. RWE and HEOR teams can track how often diagnostic tests are followed by treatment and assess test yield by payer and region, giving market access teams evidence to shape coverage policies and provider engagement.

To deepen insights further, taXonomy Pathways incorporates more than 3.6 billion de‑identified clinical notes across 340 million encounters for 43 million patients. These narrative notes capture symptoms, disease severity, imaging results, contraindications and reasons for discontinuation, giving researchers a broader view across therapeutic areas that far exceeds a claims-only approach.

Available now

taXonomy Pathways is available today. For more information, register for our webinar to see how you can close the evidence gap in your therapeutic area or schedule a meeting with our sales team.

About HealthVerity

HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry’s largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, regulatory decision-making, and public health.

Media Contact:

HealthVerity
info@healthverity.com